Skip to search formSkip to main contentSkip to account menu

BMS 387032

Known as: BMS-387032, SNS 032, SNS-032 
A small aminothiazole molecule and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. SNS-032 binds to and prevents the… 
National Institutes of Health

Related topics

Related topics

4 relations
CDK2 protein, humanCyclin-Dependent KinasesGene Expression RegulationPositive Regulation of Apoptosis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Purvalanol A, Olomoucine II and Roscovitine Inhibit ABCB1 Transporter and Synergistically Potentiate Cytotoxic Effects of Daunorubicin In Vitro
Cyclin-dependent kinase inhibitors (CDKi) have high potential applicability in anticancer therapy, but various aspects of their… 
2012
2012
Overcoming Gleevec-resistance by blocking oncogene addiction in malignant hematologic cells
In some types of tumors, malignant cells are highly dependent on the constitutive activation of a certain protein encoded by… 
2010
2010
Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line.
SNS-032 is a potent inhibitor of cyclin-dependent kinases (Cdk) 2, 7, and 9 that regulate the cell cycle and transcription. Our… 
2010
2010
Abstract 3886: Therapeutic potential of CDK inhibitors in MLL leukemias
Chromosomal rearrangements involving the human mixed - lineage leukaemia (MLL) gene at 11q23, are associated with the development… 
2008
2008
A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties.
2008
2008
Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio.
2008
2008
A Phase 1 Trial of SNS-032, a Potent and Specific CDK 2, 7 and 9 Inhibitor, in Chronic Lymphocytic Leukemia and Multiple Myeloma
SNS-032, formerly BMS-387032, is a highly selective and potent inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9. CDK2 and… 
2007
2007
Mechanism of Action of SNS-032, a Novel Cyclin Dependent Kinase Inhibitor, in Chronic Lymphocytic Leukemia: Comparison with Flavopiridol.
Cyclin dependent kinases (Cdks) not only drive cell cycle progression, but also control transcription. For example, Cdk7 and Cdk9… 
2006
2006
The cyclin-dependent kinase 2 inhibitor down-regulates interleukin-1beta-mediated induction of cyclooxygenase-2 expression in human lung carcinoma cells.
Overexpression of cyclooxygenase-2 (COX-2) is frequently observed in several human cancers, including lung, colon, and head and… 
2004
2004
PET as a biomarker of the antitumor effects of the CDK2 inhibitor BMS-387032.
2032 Background: PET is a non-invasive and sensitive technique for detecting tumors, disease staging and monitoring effects of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)